CITIC Securities Co., Ltd., China International Capital Corporation Limited

About Shanghai United Imaging Medical Technology Co., Ltd

2024 Semi-Annual Continuous Supervision Follow-up Report

CITIC Securities Co., Ltd. (hereinafter referred to as "CITIC Securities" or the "Sponsor") and China International Capital Corporation Limited (hereinafter referred to as "CICC" or the "Sponsor") as the sponsors of the initial public offering of shares and listing on the Science and Technology Innovation Board of Shanghai United Imaging Medical Technology Co., Ltd. (hereinafter referred to as "United Imaging Healthcare" or the "Company"), in accordance with the Administrative Measures for the Sponsorship Business of Securities Issuance and Listing, the Rules Governing the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange and other relevant provisions. CITIC Securities and CICC perform the duties of continuous supervision and issue this semi-annual follow-up report for continuous supervision.

1. Overview of continuous supervision

1. The sponsor has formulated a continuous supervision work system, formulated a corresponding work plan, and clarified the work requirements for on-site inspection.

2. The sponsor has signed a sponsorship agreement with the company, which has clarified the rights and obligations of both parties during the continuous supervision period, and has been reported to the Shanghai Stock Exchange for the record.

3. During the period of continuous supervision, the sponsor will carry out continuous supervision through daily communication with the company and on-site return visits.

4. During the period of continuous supervision, the sponsor shall perform the duties of continuous supervision in accordance with the requirements of relevant laws and regulations and normative documents, including:

(1) Consult the articles of association, the rules of procedure of the three sessions and other corporate governance systems, and the materials of the three sessions;

(2) Check the company's internal control systems such as financial management, accounting and internal audit;

(3) Check the details of the company's capital transactions with the controlling shareholder, actual controller and its related parties, as well as relevant internal review documents and information disclosure documents;

(4) Check the relevant systems of the company's raised funds, information disclosure documents and decision-making procedures for the use of raised funds, bank statements of special accounts for raised funds, and detailed accounts for the use of raised funds;

(5) Conduct interviews with senior management of the company;

(6) Conduct public information inquiries about the company and its controlling shareholders, actual controllers, directors, supervisors, and senior managers;

(7) Inquire about the commitments announced by the company and verify the fulfillment of the commitments;

(8) Pay attention to media reports related to the issuer through public network search, public opinion monitoring, etc.

2. Problems found by the sponsor and the sponsor representative and their rectification

Based on the aforesaid continuous supervision work carried out by the sponsor, the sponsor and the sponsor representative did not find any major problems with the company during the continuous supervision period.

3. Major risk matters

(1) Risks of international operation and business expansion

The company attaches great importance to the expansion and sales of high-end medical imaging diagnosis and radiotherapy products in overseas markets, and has achieved sales in United States, Japan, Europe, Africa and Southeast Asia and other countries and regions. During the reporting period, the company's overseas business income was 933 million yuan (according to the location of the end customer's installed capacity), accounting for 17.49% of the company's business income, a year-on-year increase of 29.94%, and the overall trend remained upward year by year.

However, the regulatory policies and regulations for medical devices in different overseas markets and regions are usually different, and there are uncertainties in the international situation, as well as differences in the supervision of intellectual property protection, unfair competition, consumer protection, etc. With the further expansion of overseas business scale, the overseas legal environment involved in the company will become more complex and changeable, and if the company cannot respond to changes in the overseas market environment and policy environment in a timely manner, it will have an adverse impact on the company's overseas business expansion and operation. The details are as follows:

1. Policy and approval risks

In recent years, the international situation has been full of ups and downs, various uncertain and unstable factors have emerged frequently, the international trade environment has become increasingly complex, trade frictions and disputes have continued, and geopolitical factors may have an adverse impact on the economy and trade of some countries or regions. Some countries have always had strong approval barriers to the licensing of high-end medical device operation and sales, and the time period for completing product registration is long, making market access difficult. Different overseas markets and regional pairs

Regulatory policies and regulations for medical devices are often different, the political and economic situation is uncertain, and there are also differences in the supervision of intellectual property protection, unfair competition, consumer protection, etc.

2. Market competition risk

GE Healthcare, Siemens Healthineers, Philips Healthcare, and other companies have dominated many fields of medical devices for many years, and have significant advantages in academics, clinical evidence, customer awareness, global supply chain integration, product technology development, overseas after-sales service, and brand influence. In the face of international market competition, if the company cannot maintain and continue to strengthen its competitive advantage and core competitiveness, the market share and price of the company's products may decline due to intensified market competition.

3. The risk of expanding overseas sales channels

In terms of the overall layout of overseas strategy, the company will promote overseas business development from the aspects of overseas product registration, team and network construction, production base and supply chain layout for the target market. As of the end of the reporting period, the company has built overseas teams through 19 overseas subsidiaries, but the construction time of overseas sales channels is relatively short, if the company cannot effectively integrate overseas sales teams and local dealer channels, resulting in the company's products can not quickly open overseas markets, it will have an adverse impact on the company's overseas market share and business development.

In view of the above risks, the company will comprehensively strengthen the management and layout of global R&D, production, sales, service, supply chain, etc., scientifically make decisions, promote the implementation of the company's various strategic plans and business layouts in a reasonable and orderly manner, and further enhance the company's brand influence and recognition in the international market through effective market activities and industry-university-research-medical cooperation.

(2) Market competition risks

According to the research report of CIC, the market size of medical imaging equipment in China has exceeded 500 in 2020

billion, the market grew at a CAGR of 12.4% from 2015 to 2020. Although building a "healthy China"

It has risen to a national strategy, and factors such as the rapid expansion of China's big health market, the construction of national medical centers, the construction of national regional medical centers, the comprehensive capacity improvement of county-level hospitals of the "Thousand County Project", and the release of the "Large-scale Medical Equipment Configuration License Management Catalogue (2023)" have all promoted the potential demand for medical imaging equipment, but the company is still facing a fierce market competition environment.

On the one hand, China's high-end medical imaging equipment market has been monopolized by foreign-funded enterprises such as GE Healthcare, Siemens Healthineers and Philips Healthcare in the past

Occupy more than 90% of the market share, and after more than ten years of development of domestic medical imaging equipment technology, the import substitution trend of domestic brands has become more and more obvious, and the market share of imported brands has shown a downward trend, but import manufacturers are still in a leading position in the market by virtue of their brand advantages, channel advantages and technical advantages created over the past years; On the other hand, the company is also facing competition from domestic medical imaging equipment manufacturers, including Mindray Medical, Neusoft Medical, Wandong Medical, etc., which are actively deploying in the fields of XR, CT, MR and PET/CT, and continuously increasing their development efforts in the medical imaging equipment market. In the face of the competition of the above-mentioned domestic and foreign brands, if the company cannot maintain and continue to strengthen its competitive advantage and core competitiveness, the market share and price of the company's products may decline due to intensified market competition.

In view of the above risks, the company will continue to strengthen core technology research and next-generation product investment, and timely judge market trends and needs; The company takes cost management, product quality management and service quality management as the traction, and pays attention to the quality requirements of the whole life cycle of products; The company will carry out talent reserves, technical reserves, product reserves and customer expansion on a global scale, deepen the strategic layout of internationalization, and enhance the competitiveness of the global market.

(3) Financial risks

1. Risk of changes in tax policies

The company and some of its subsidiaries are high-tech enterprises recognized by law, and can enjoy preferential income tax policies for high-tech enterprises when they meet all the conditions for enjoying the preferential tax treatment for high-tech enterprises. In the future, if the above-mentioned preferential tax policies change or the company does not meet the preferential tax conditions and cannot continue to enjoy the relevant preferential policies, the company's tax burden will be increased, which will have a certain impact on the company's business. The company will continue to pay attention to the trend of tax policies, consolidate and strengthen its own R&D strength, increase R&D investment, and consolidate the qualification of high-tech enterprises.

2. Risk of exchange rate fluctuations

Affected by factors such as changes in the international situation and environment, the difficulty of exchange rate risk management may increase in the future, and exchange rate fluctuations will directly affect the amount of the company's exchange gains and losses, which may have a certain impact on the company's operating business. The company attaches great importance to exchange rate risk management, takes short-term and medium- and long-term measures at the same time, and reasonably uses financial and operational methods to deal with exchange rate fluctuation risks.

4. Major violations

Based on the above-mentioned continuous supervision work carried out by the sponsor, the sponsor did not find any material violations of the company during the continuous supervision period.

5. Reasons and reasonableness of changes in major financial indicators

In the first half of 2024, the company's main financial data and indicators are as follows:

Unit: 10,000 yuan, %

Main accounting data January-June 2024 Same period last year This reporting period is the same as that of the previous year

Period increase or decrease

Operating income 533,348.63 527,134.58 1.18

Net profit attributable to shareholders of listed companies 95,021.19 93,777.69 1.33

moistening

Deductions attributable to shareholders of listed companies 79,793.44 78,698.11 1.39

Net profit from non-recurring gains and losses

Net cash flow from operating activities -62,459.24 -51,145.97 Not applicable

forehead

Key Accounting Data June 30, 2024 End of Previous Year The end of the reporting period was compared with the previous year

The end of the degree increases and decreases

Net assets attributable to shareholders of listed companies 1,958,782.84 1,886,635.36 3.82

give birth

Total assets 2,670,452.13 2,533,614.03 5.40

Main Financial Indicators January-June 2024 Same period last year The reporting period was the same as that of the previous year

Period increase or decrease (%)

Basic earnings per share (RMB/share) 1.16 1.14 1.75

Diluted earnings per share (RMB/share) 1.16 1.14 1.75

Basic 0.97 0.95 2.11 after deducting non-recurring gains and losses

Earnings per share (RMB/share)

The weighted average return on equity (% 4.93 5.22 decreased by 0.29 percentage points

）

After deducting non-recurring gains and losses, the weighted 4.14 4.38 decreased by 0.24 percentage points

Average Return on Equity (%)

The ratio of R&D investment to operating income 19.07 17.37 increased by 1.70 percentage points

（%）

1. The operating situation, financial status and main factors affecting the operating performance in the reporting period

During the reporting period, the company achieved operating income of 5.333 billion yuan, a year-on-year increase of 1.18%, benefiting from the positive

Market expansion and the proportion of core product sales increased. At the same time, the accelerated commercialization of new products, the expansion of the global market share of mature products, and the increase in the proportion of service revenue also drove the steady growth of operating income. Specifically, the revenue performance of each product line is good, and the core product line continues to maintain its market leadership position, among which:

The CT business line was 1.618 billion yuan, the MR business line was 1.685 billion yuan, the MI business line was 743 million yuan, and the XR business was in the XR business

line 256 million yuan, RT business line 242 million yuan; service revenue was 617 million yuan, a year-on-year increase of 23.84%.

Service revenue accounted for 11.57%, and the proportion of service revenue increased by 2.12 percentage points year-on-year, and end-user satisfaction was strongly guaranteed.

In terms of profit indicators, the company achieved a net profit attributable to shareholders of listed companies of 950 million yuan, a year-on-year increase of 1.33%; The gross profit margin was 50.37%, a year-on-year increase of 1.66 percentage points. During the reporting period, the company strengthened cost control, flexibly responded to market demand, continuously improved the management structure, and improved operational efficiency.

As a leading global medical company, United Imaging Healthcare has always attached great importance to R&D and innovation. In the first half of 2024, the company's R&D investment was 1.017 billion yuan, a year-on-year increase of 11.11%, and it has maintained high investment for many consecutive years.

2. The main reasons for the increase or decrease of more than 30% in the above table

During the reporting period, the increase or decrease of the relevant items in the above table of the company did not exceed 30%.

Sixth, the changes in core competitiveness

(1) The company's core competitiveness

The company is a leading medical technology enterprise in China and one of the few medical technology companies in the world that has mastered the core technology of high-end medical imaging diagnostic products, radiotherapy products and life science instruments, and has the ability to manage the whole life cycle of products from R&D, production, sales to after-sales maintenance.

1. Comprehensive product layout and leading product performance

(1) Comprehensive product coverage

The company has formed a rich product line around high-end medical imaging equipment, covering MR, CT, XR,

Diagnostic products such as PET/CT, PET/MR, radiation therapy products such as conventional RT, CT-guided RT and animals

Life science instruments such as MR and animal PET/CT can meet the needs of everything from preclinical research to diagnosis to treatment. The company's equipment is equipped with self-developed medical image processing software and advanced applications, which can realize the organic combination of research, diagnosis, treatment and program, and provide a one-stop solution for precision diagnosis and treatment.

(2) Advanced product performance

A number of products developed by the company have created the "first" in the industry or in China, including the industry's first PET/CT product with 4D whole-body dynamic scanning function, uEXPLORER (Total-bodyPET/CT), which was awarded in 2018

"Top 10 Technological Breakthroughs in the World" by Physics World Magazine in United Kingdom; The industry's first 75cm pore size 3.0TMR product, uMR Omega, has a number of patented technologies such as zero liquid helium volatilization technology, active/passive shimming technology, and quench protection technology. The industry's first diagnostic-grade CT-guided all-in-one radiotherapy accelerator, uRT-linac

all-in-one CT linear accelerator and other products; The industry's first whole-body imaging MRI system, the uMR Jupiter 5T,

As a "special project for the research and development of digital diagnosis and treatment equipment" of the "13th Five-Year Plan" national key research and development plan, this product has overcome the core components and core technical problems of ultra-high-field magnetic resonance and realized ultra-high-field whole-body clinical imaging.

2. Strong comprehensive R&D capabilities

(1) Vertical R&D system

The company has built a vertical innovation system that runs through technology, products and software, and carries out core technology research and development around the core components of each product line, laying a solid foundation for realizing independent and controllable core technologies and casting product competitiveness barriers. The company's self-research ratio ranks in the forefront of the industry, and the main core components of each product line are self-developed and self-produced.

(2) Platform-based R&D model

The company has built a general software and general hardware R&D platform, which provides a foundation for technology reference and exchange, product integration and iteration with a cross-product line platform R&D model. At the R&D level, the general underlying architecture provides innovative convenience for the development of multimodal products. At the project level, shared software and hardware design can improve R&D efficiency and accelerate product iteration. At the product level, with a unified system and unified industrial design and interface design, the company's different product lines maintain a high degree of consistency in brand image and user experience, which is conducive to the enhancement of brand influence and the continuous promotion of products.

(3) Cutting-edge innovation strategy

The company guides the direction of innovation through forward-looking research and market trends. On the one hand, the company actively deploys forward-looking research, explores and grasps new opportunities for the transformation and development of the industry, and provides technical reserves for the company's R&D and innovation; On the other hand, each product division has formed a close connection with the market, and continues to promote the technological innovation and iterative upgrading of the whole line of products through rapid feedback on market demand.

(4) Global R&D talent pool

Talent is the foundation of the company's continuous R&D and innovation, and the company has built a global vision led by a number of top scientists and personnel with deep industry management and R&D experience through independent training and external introduction

R&D echelon. As of the end of the reporting period, the company had a total of 7,859 employees, including 3,102 R&D personnel, accounting for 39.47% of the company's total employees.

3. Complete intellectual property layout

The intellectual property system is the core support for technological innovation, and it is also an important guarantee for the sustainable development and globalization of enterprises. The company has established a complete database and intellectual property management platform to realize the platform management of the whole life cycle of intangible assets. The company's intellectual property system covers patents, trademarks, copyrights and technical secrets. As of the end of the Reporting Period, the Company had more than 10,000 patent-based intellectual property applications, of which invention patent applications accounted for more than 80% of the total patent applications, and the Company had obtained more than 5,500 intellectual property rights authorizations, including more than 3,300 invention patents. At the same time, the company strictly protects the company's technical secrets in accordance with the "Information Security Management Measures" and the "Trade Secret Management System", and strives to create a comprehensive intellectual property layout system to protect the company's technological innovation achievements from different angles.

(1) Forward-looking layout strategy

Since its establishment, the company has been taking the patent layout strategy as an important means to strengthen its competitiveness, and has continued to build patent barriers based on its own technology path, cutting-edge technology in the industry and market expansion direction. The company's patent mining mechanism runs through the whole life cycle of technology research and development, and the patent application covers a wide range of products. At the same time, in the process of research and development, the company plans in advance for the technologies that may be implemented in the future and provides patent protection to seize the opportunity to ensure that the company obtains more basic patents and higher layout efficiency.

In terms of trademarks, in the early days of the company's establishment, it carried out trademark layout in line with the product launch plan, and used the advantages of the Madrid trademark system to carry out global trademark layout, laying the foundation for overseas market expansion.

Combined with its own technical path, cutting-edge trends in the industry and market expansion direction, the company has formed a set of offensive and defensive intellectual property layout.

(2) Establishment of a systematic system

Combined with its own development strategy, the company has established a comprehensive and systematic intellectual property management system, covering the acquisition, maintenance and application control of intellectual property rights. At the level of risk control, it can support intellectual property risk identification and legal dispute resolution; At the level of documents and regulations, the company has established control procedures that include intellectual property documents and laws and regulations; At the level of information security, the company implements strict confidentiality management of intellectual property information resources.

4. Three-dimensional marketing network

The company combines direct sales and distribution models to create a diversified three-dimensional marketing system covering domestic and foreign markets, from top scientific research institutes, universities, tertiary hospitals and grassroots institutions. The company actively implements the national hierarchical diagnosis and treatment implementation strategy, realizes the penetration of the primary medical market through rich products, and innovates equipment and the Internet and imaging

The combination of cloud technology promotes the sinking of medical resources. In overseas markets, as of June 30, 2024, the Company

It has established a sales network in United States, Japan, Poland, Australia, New Zealand, Korea, South Africa, Morocco, Malaysia and other countries and regions around the world, and the company's products have successfully entered more than 70 countries and regions such as United States, Japan, Korea, New Zealand, Italy and India.

5. Perfect after-sales service

Focusing on customer experience, the company has built a perfect customer service system around regular after-sales needs, emergency response needs and feedback needs. The company has established an after-sales team that pays attention to details and strives for perfection to provide customers with comprehensive services covering training, installation, repair, upgrade, maintenance and other aspects. In addition, the company attaches great importance to continuous communication with customers and obtaining feedback to promote the product optimization and upgrading of the R&D team.

6. Integration and innovation of industry, university, research and medicine

The company has gradually transformed from a single dimension of empowering clinical practice with products and technology to building a deep integration and innovation system of industry, university, research and medicine with all-round scientific and technological support. The company has opened up the whole chain of "basic research-clinical application-translational medicine-industrial transformation", driven product definition, performance optimization, application expansion and clinical demonstration with clinical needs and major medical problems, formed a closed-loop management from innovation to commercial transformation, and continued to expand innovation leadership and business competitiveness.

(2) Changes in core competitiveness

During the period of continuous supervision, the sponsor did not find any material adverse changes in the company's core competitiveness by reviewing the listed companies and market information in the same industry, reviewing the company's prospectus, periodic reports and other information disclosure documents, and interviewing the company's senior management.

7. Changes in R&D expenditure and R&D progress

(1) Changes in R&D expenditure

Unit: 10,000 yuan; Amplitude: %

Item January-June 2024 Year-on-year change

Expensed R&D investment 82,602.29 88,523.09 -6.69

Capitalized R&D investment 19,102.64 3,014.07 533.78

Total R&D investment 101,704.94 91,537.17 11.11

The total R&D investment accounted for 19.07 17.37 of operating revenue, an increase of 1.7 percentage points

Proportion (%)

The proportion of capitalization of R&D investment was 18.78 3.29, an increase of 15.49 percentage points

（%）

(2) R&D progress

During the period of continuous supervision, the company's main research projects are as follows:

Unit: 10,000 yuan

Preface Expected total investment Current investment Cumulative investment Progress or to achieve specific application of technology

No. Project Name Capital Scale Amount Amount Phased Target Level Prospect

achievement

1 MR R&D items 10,400.00 1,152.20 8,839.49 Obtained Received Note Industry Applicable to Pro

Purpose 1 Registration Certificate Leader Bed Scene

The MR R&D section was awarded the Note Industry Applicable Pro

2 2 5,000.00 1,273.24 4,087.08 Registered Certificate Leading Bed and Research

Witness scenario

3 MR R&D items 14,800.00 3,899.02 5,171.71 Ongoing Acquisition Note Industry Applicable to Pro

The third book certificate leads the bed scene

The MR R&D section was awarded the Note Industry Applicable Pro

4 Mesh4 20,000.00 3,168.45 13,412.03 Registered Certificate Leading Bed and Research

Witness scenario

5 MR R&D items 10,900.00 1,244.09 7,203.93 Obtained Received Note Industry Applicable Pro

Item 5 Registration Certificate Registration Certificate Leading Bed Scene

MR R&D items have been obtained by the Industries for Pro

6 13,700.00 1,007.22 8,246.48 Registration Certificate Leading Bed and Research

scenario

MR R&D items obtained note industry for Pro

7 7 5,700.00 945.28 4,193.69 Ongoing Accreditation Leading Bed and Scientific Research

scenario

MR R&D items have been obtained by the Industries for Pro

8 ITEM 8 6,400.00 578.97 3,195.34 REGISTRATION CERTIFICATE LEADING BED AND SCIENTIFIC RESEARCH

scenario

9 CT R&D items 4,600.00 622.14 2,707.38 Ongoing Acquisition Note Industry Applicable to Pro

The first book certificate leads the bed scene

The CT R&D section was awarded the Note Industry for Pro

10 25,000.00 1,209.76 15,758.84 Registered Certificate Leading Bed and Research

Witness scenario

Preface Expected total investment Current investment Cumulative investment Progress or to achieve specific application of technology

No. Project Name Capital Scale Amount Amount Phased Target Level Prospect

achievement

CT R&D items have been obtained by the Industries for Pro

11 3 9,500.00 448.93 6,489.19 Registration Certificate Leading Bed and Research

scenario

12 CT R&D items 9,000.00 489.73 5,917.23 Obtained Received Note Industry Applicable to Pro

Item 4 Registration Certificate Register Leading Bed Scene

CT R&D items obtained note industry for Pro

13 FIVE 14,000.00 757.07 7,439.25 Conducting Registered Certificates Leading Bed and Scientific Research

scenario

14 CT R&D items 3,200.00 359.51 914.41 Ongoing Acquisition Note Industry Applicable to Pro

The sixth book certificate leads the bed scene

CT R&D items obtained note industry for Pro

15 7 8,800.00 1,855.35 7,800.81 Conducting Registered Certificates Leading Bed and Scientific Research

scenario

CT R&D items obtained note industry for Pro

16 Mesh 8 14,400.00 2,862.47 7,046.32 Ongoing Registered Certificate Leading Bed and Research

scenario

17 CT R&D items 5,800.00 1,161.78 1,161.78 Obtained Received Note Industry Applicable to Pro

ITEM 9 Registration Certificate Leads Bed Scene

18 CT R&D items 4,800.00 797.27 1,180.08 In progress Acquisition Note Industry Applicable to Pro

Ten books of certificates lead the bed scene

CT R&D items obtained note industry for Pro

19 ITEM 11 2,000.00 337.02 337.02 Conducting Registered Certificates Leading Beds and Scientific Research

scenario

20 RT R&D items 6,000.00 946.29 3,495.30 Ongoing Acquisition Note Industry Applicable to Pro

The first book certificate leads the bed scene

21 RT R&D items 36,500.00 4,736.49 26,401.02 Obtained Received Note Industry Applicable to Pro

Item 2 Registration Certificate Register Certificate Leading Bed Scene

22 RT R&D items 18,800.00 1,824.51 11,175.87 Ongoing Acquisition Note Industry Applicable to Pro

The third book certificate leads the bed scene

23 RT R&D items 3,000.00 843.16 2,983.63 In progress Acquisition Note Industry Applicable to Pro

The fourth book certificate leads the bed scene

The software R&D project part was awarded the Note Industry for Pro

24 1 24,500.00 6,354.48 16,189.06 Registered Certificate Leading Bed Scene

proof

25 Software R&D items 23,000.00 1,564.93 14,646.86 In progress Acquisition Note Industry Applicable to Pro

The second book certificate leads the bed scene

Support Shadow

Software R&D items like products for the industry are applicable to Pro

26 Mesh 3 13,600.00 1,233.62 9,024.14 Mass production in progress Leading bed scenario

and new production

product development

Preface Expected total investment Current investment Cumulative investment Progress or to achieve specific application of technology

No. Project Name Capital Scale Amount Amount Phased Target Level Prospect

achievement

27 XR R&D items 15,000.00 1,815.88 10,212.42 Obtained Received Note Industry Applicable to Pro

Purpose 1 Registration Certificate Leader Bed Scene

The XR R&D project was partially awarded the Note Industry for Pro

28 28,300.00 4,003.24 22,162.21 Registered Certificate Leading Bed Scene

proof

29 XR R&D 6,100.00 615.87 3,132.85 Obtained Received Note Industry Applicable to Pro

Item 3 Registration Certificate Registration Certificate Leading Bed Scene

MI R&D items have been obtained by the industry for Pro

30 1 5,000.00 274.04 3,013.54 Registration Certificate Leading Bed and Research

scenario

MI R&D items have been obtained by the industry for Pro

31 Mesh2 7,000.00 1,482.95 5,405.67 Registration Certificate Leading Bed and Research

scenario

32 MI R&D items 13,500.00 1,011.88 8,998.36 Obtained Received Note Industry Applicable to Pro

Item 3 Registration Certificate Registration Certificate Leading Bed Scene

The MI R&D project part was awarded the Note Industry for Pro

33 Mesh 4 16,800.00 1,799.91 11,725.51 Registered Certificate Leading Bed Scene

proof

MI R&D items obtained note industry for Pro

34 5 3,000.00 233.46 1,413.58 Conducting Registered Certificates Leading Bed and Research

scenario

35 MI R&D items 7,300.00 919.61 1,458.96 Ongoing Acquisition Note Industry Applicable to Pro

The sixth book certificate leads the bed scene

Get a bet

Part of the component research and development project has been registered and applied to the industry

36 Mesh 1 8,800.00 1,468.43 5,771.00 Registered Support Shadow Leading Spare Parts

Certified products

mass production

Component R&D items support industry application design

37 Mesh II 1,900.00 316.86 877.00 Ongoing image products Leading spare parts

mass production

Component R&D items support industry application design

38 Mesh 3 1,500.00 186.13 1,058.76 In progress Like products Leading spare parts

mass production

Component R&D items support industry application design

39 Mesh4 11,000.00 1,175.59 6,850.03 In progress Like products Leading spare parts

mass production

40 Ultrasound R&D items 25,300.00 6,327.57 18,493.02 Ongoing Acquisition Note Industry Applicable to Pro

The first book certificate leads the bed scene

41 Life Science Instrument 2,200.00 587.11 2,165.39 Mass production on scientific research promotion international applicable to science

The first project is a leading research scenario in the city

Preface Expected total investment Current investment Cumulative investment Progress or to achieve specific application of technology

No. Project Name Capital Scale Amount Amount Phased Target Level Prospect

achievement

Listed on the market

Life Science Instrument Scientific Research Promotion Industry Applicable to Branch

42 Instrument Project 2 3,000.00 355.45 1,659.25 Ongoing Broad and Quantitative Leading Research Scenario

Listed on the market

Life Science Instrument Scientific Research Promotion Industry Applicable to Branch

43 Item 3 6,400.00 1,115.16 5,795.78 Ongoing Broad and Quantitative Leading Research Scenario

Listed on the market

Get next

44 Next Generation Products 5,000.00 1,201.96 3,959.62 Ongoing Generation Industry Applicable to Pro

Pre-research project product and technology leading bed scene

Surgical planning

Sum / 480,500.00 66,564.08 309,170.89 / / / /

plan

8. Whether the progress of the new business is consistent with the previous information disclosure (if any)

During this ongoing supervision period, the sponsor discloses the information by reviewing the company's prospectus, periodic reports and other information

Disclosure of documents, interviews with senior management of the company, based on the above-mentioned verification procedures, the sponsor did not find the company

There is new business.

9. The use of the raised funds and whether they are compliant

During the period of continuous supervision, the sponsor inspected the company's management and use system for raised funds and the special account for raised funds

Bank statements and detailed accounts of the use of raised funds, and random checks and inspections of vouchers for the payment of large amounts of raised funds

The use of information disclosure documents and decision-making process documents for the raised funds, and the on-site inspection of the raised funds investment project site,

Understand the progress of project construction and the use of funds, and obtain the report on the use of raised funds issued by listed companies

and the annual audit accountant issued by the use of the raised funds of the assurance report, interviews with the company's senior management.

On April 25, 2024, the company held the sixth meeting of the second board of directors to deliberate and approve the "About Adjustment".

The proposal for the internal investment structure of the entire fundraising project and the extension of the company, in order to accelerate the construction of the marketing service network

Combined with the actual construction of the current fund-raising project, the main body of the fund-raising investment project and the fund-raising investment project will be raised

Under the condition that the purpose of funds and the total amount of investment remain unchanged, the internal investment structure and forecast of the "marketing service network project" will be adjusted

The time it takes to reach the intended usable state. Except for the above deferrals, the Company does not exist for the first half of 2024

Change the investment project of the raised funds.

Based on the aforesaid verification procedures, the sponsor believes that the Company has established a fund management during the period of continuous supervision

The necessary decision-making procedures and information disclosure procedures have been fulfilled for the use of raised funds, and no illegal use of raised funds has been found based on the above-mentioned inspections.

10. Shareholding, pledge, freezing and reduction of shareholdings, pledges, freezes and holdings of controlling shareholders, actual controllers, directors, supervisors and senior managers

During the period of continuous supervision, the number of shares held by the Company's controlling shareholder, United Imaging Medical Technology Group Co., Ltd., and the shareholders controlled by Xue Min, the actual controller of the Company, Shanghai Yingsheng Investment Partnership (Limited Partnership) and Shanghai Yingzhi Investment Partnership (Limited Partnership), did not change, and there were no other pledges, freezes and reductions.

Ningbo Yingju, Ningbo Yingli, Ningbo Yingjian, Ningbo Yingkang, Shanghai Yingdong (hereinafter collectively referred to as "employees".)

shares of the company, accounting for 7.53% of the company's total share capital, held a total of 62,055,909 shares. March 2024

On March 30, the company disclosed the "Announcement on the Share Reduction Plan of United Imaging Medical" (Announcement No.: 2024-006) on the website of the Shanghai Stock Exchange (www.sse.com.cn), according to which the employee stock ownership platform intends to reduce the total number of shares through block trading or centralized bidding not more than 8,240,000 shares, and the total number of shares will not exceed the total shares of United Imaging Healthcare

1% of servings. On July 24, 2024, the company was listed on the website of the Shanghai Stock Exchange (www.sse.com.cn).

According to the "Announcement on the Results of United Imaging Medical's Shareholder Reduction of Shareholdings" (Announcement No.: 2024-041), during the shareholding reduction plan, the employee shareholding platform reduced its holdings by a total of 7,471,530 shares through centralized bidding and block trading

shares, accounting for 0.91% of the company's total share capital. As of July 31, 2024, the company's directors, supervisors, high

The changes in the indirect shareholdings of senior management personnel and core technical personnel are as follows:

As of Exists

Name Position Indirect Holding at the beginning of the period 2024.7.31 Reason for change Qualitative

Shares (shares) Shares Pledge and freeze

(shares) Settlements

Chairman of the Board and Co-Chief Executive

Zhang Qiang Executive Officer, Core Technology 1,869,290 1,507,041 Personal capital needs,

personnel

GUOSHENG Director, General Manager, Joint Personal Capital Needs

TAN CEO 2,378,810 2,178,810 /

JUN BAO DIRECTOR & PRESIDENT 2,378,810 2,178,810 Personal capital needs /

Directors and secretaries of the board of directors have personal financial needs

TAO CAI, Chief Investment Officer 1,861,677 1,561,677 /

Wan Lijuan Chairman of the Board of Supervisors 930,839 880,839 Personal capital needs /

Wang Yang Supervisor 206,853 186,853 Personal capital needs /

Xia Fenghua Senior Vice President 1,965,104 1,473,828 Personal capital needs /

Senior Vice President, Chief Officer

HONGDI LI Technical Officer, Core Technology 2,378,810 2,355,305 Personal capital needs /

personnel

Yu Yeheng Senior Vice President 1,034,265 775,699 Personal capital needs /

Miao Hong Senior Vice President 1,965,104 1,665,104 Personal capital needs /

Lv Yunlei Vice President 103,427 90,427 Personal capital needs /

Wang Shumei Vice President 620,559 590,559 Personal capital needs /

The Company's supervisors, senior managers, core technical personnel and other core employees participated in the Strategic Placement No. 1 Collective Asset Management Plan of the Science and Technology Innovation Board (hereinafter referred to as "United Imaging Healthcare 1.") through the employees of CITIC Securities United Imaging Healthcare

4,493,640 shares, 2,923,058 shares at the end of the reporting period), CITIC Securities

United Imaging Healthcare's employees participated in the Strategic Placement No. 2 Collective Asset Management Plan of the Science and Technology Innovation Board (hereinafter referred to as "United Imaging Healthcare").

No. 2 Employee Asset Management Plan", 3,695,573 shares were allotted, and 1,939,460 shares were held at the end of the reporting period).

Employees of United Imaging Medical participated in the No. 3 Collective Asset Management Plan of the Strategic Placement of the Science and Technology Innovation Board (hereinafter referred to as "United Imaging Medical".

Employee Asset Management Plan No. 3", 842,529 shares were allocated, and 471,403 shares were held at the end of the reporting period).

When the employees of the company participated in the strategic placement of the No. 4 collective asset management plan of the Science and Technology Innovation Board

Strategic Placement. As of the end of the reporting period, the changes in the indirect shareholdings of supervisors and senior management were as follows:

Name Position Indirect shareholding at the beginning of the period Indirect shareholding at the end of the period Increase or decrease

Causes

Wan Lijuan, the Board of Supervisors, directly holds the salary of United Imaging Medical's No. 1 employee, and directly holds the salary of United Imaging Healthcare's No. 1 employee's personal resources

Chairman Shares of the Management Program 15,486,913.05 Shares of the Management Program 13,236,913.05 Shares of the Funding Requirements

Wang Yang, Supervisor, directly holds the salary of United Imaging Medical's No. 3 employee - personal assets

Tube plan 800,116.67 share of the gold requirements

Xia Fenghua Senior Deputy directly holds the salary of United Imaging Medical's No. 1 staff and directly holds the salary of United Imaging Medical's No. 1 staff and personal resources

President 20,994,007.19 share of the plan 9,352,383.19 share of the plan

Yu Yeheng, senior deputy directly holds the salary of United Imaging Medical's No. 1 staff - personal capital

President of the management plan 6,998,283.44 share of the gold requirements

Miao Hong, senior deputy, directly holds the salary of United Imaging Medical's No. 2 employee, directly holds the salary of United Imaging Medical's No. 2 employee, and his personal qualifications

President Tube Plan 29,964,043.15 Share Tube Plan 9,397,079.09 Share Gold Requirements

Lv Yunlei, Vice President, directly holds the salary of United Imaging Medical's No. 2 employee, and directly holds the salary of United Imaging Healthcare's No. 2 employee's personal resources

Pipe plan 9,190,171.56 share of the tube plan 8,740,171.56 share of the fund requirement

Wang Shumei, Vice President, directly holds the salary of United Imaging Medical's No. 2 employee, and directly holds the salary of United Imaging Healthcare's No. 2 employee's personal resources

Shares of the management plan 20,000,680.56 Shares of the management plan 8,500,680.56 shares of the gold requirements

11. Other matters on which the sponsor deems it necessary to express its opinion

Based on the above-mentioned continuous supervision work carried out by the sponsor, during the period of continuous supervision, the sponsor did not find any other matters on which it should express its opinion.

This report does not constitute any investment advice on listed companies, and the sponsor reminds investors to carefully read the semi-annual reports and other information disclosure documents of listed companies.

(No text below)

(There is no text on this page, it is the signed and stamped page of the "CITIC Securities Co., Ltd. and China International Capital Corporation Limited on the 2024 Semi-annual Continuous Supervision and Tracking Report of Shanghai United Imaging Medical Technology Co., Ltd." by CITIC Securities Co., Ltd.)

Sponsor Representative:

Jiao Yanyan Shao Caijie

CITIC Securities Co., Ltd

YYYYYYYYYYYYYYYYY

(There is no text on this page, it is the signed and stamped page of the "2024 Semi-annual Continuous Supervision and Tracking Report of CITIC Securities Co., Ltd. and China International Capital Corporation Limited on Shanghai United Imaging Medical Technology Co., Ltd." by China International Capital Corporation Limited)

Sponsor Representative:

Zhang Jianke, Zhang Xiaoyong

China International Capital Corporation Limited

YYYYYYYYYYYYYYYYY